Erythropoietin has recently been shown to have effects beyond hematopoiesis such as prevention of neuronal and cardiac apoptosis secondary to ischemia. In this study, we evaluated erythropoietin's in vivo protective potential in the reperfused rabbit heart following ventricular ischemia. We show that "preconditioning" with erythropoietin activates cell survival pathways in myocardial tissue in vivo and adult rabbit cardiac fibroblasts in vitro. These pathways activated by erythropoietin in both whole hearts and cardiac fibroblasts are also activated acutely by ischemia/reperfusion injury. Moreover, in vivo studies indicate that erythropoietin treatment either prior to or during ischemia significantly enhances cardiac function and recovery, including left ventricular contractility, following myocardial ischemia/reperfusion. Our data indicate that a contributing in vivo cellular mechanism of this protection is mitigation of myocardial cell apoptosis. This results in decreased infarct size as evidenced by area at risk studies following in vivo ischemia/reperfusion injury, translating into more viable myocardium and less ventricular dysfunction. Therefore, erythropoietin treatment may offer novel protection against ischemic heart disease and may act, at least in part, by direct action on cardiac fibroblasts to alter survival and other pathways during post-ischemia ventricular remodeling.
Introduction
Erythropoietin (EPO), originally coined for its role in promoting erythrocyte proliferation, differentiation and survival (1) has recently been shown to play a protective role in the brain (2) , spinal cord (3), retina (4), skeletal muscle (5) and most recently, the myocardium (6, 7) . The paradigm for EPO signaling has been delineated in erythroid cells (8) and subsequently in neuronal cells (9) . In cells expressing the cytokine receptor for erythropoietin (EPO-R), stimulation provides cellular protection by inhibiting apoptosis involving specific protein kinase cascades, including the stress-responsive Janus-associated kinase-2 (Jak2), phosphatidylinositol-3 kinase (PI3K)/Akt (10) and ras-MAP kinase pathways (8, 9) . These pathways are present in myocardial tissue lending themselves to be available if EPO and EPO-R signaling is indeed active in the heart. In fact, the JAK-STAT pathway has been shown to offer pre-conditioning protection in ischemia/reperfusion (I/R) injury (11) and cardiac Akt activity is associated with decreased apoptosis following ischemic injury (12) . Importantly, the EPO-R is expressed in the heart (13), providing a potential role for EPO in myocardial regulation.
Cardiac I/R injury depresses myocardial contractile function (14) , which is associated, at least in part, with cardiomyocyte apoptosis (15) . Cell death observed within the first few hours of myocardial ischemia occurs predominantly via apoptotic mechanisms (15) (16) (17) . It is only during the latter stages of ischemic injury that necrotic myocytes appear in larger quantities (16) .
Reperfusion significantly decreases the volume of myocardium that undergoes apoptosis (15, 17) by permitting potentially viable cells to rekindle arrested cellular metabolism, replenish depleted energy stores, repair accrued injury, and ultimately resume normal contractile function. Of potential interest in this process in the heart, both EPO production and EPO-R expression are stimulated by hypoxia (via hypoxia-inducible factor, HIF-1α) (18) , which has been shown to be Parsa et al. Revised M3: 14099 Page 4 a key player in cardiac preconditioning (19, 20) . EPO production during hypoxia occurs via HIF-1α which also induces expression of several glycolytic enzymes to reorient energy metabolism toward favoring survival during hypoxia (21) .
Prior to any hematopoietic effect, acute EPO treatment reduced infarct size and decreased myocardial apoptosis following myocardial infarction (MI), mediated via the PI3K/Akt pathway in the heart (7). Protection against hypoxia-induced cellular apoptosis was also seen with EPO using a cardiomyoblast cell line (7) . We hypothesized that this cardioprotection afforded by EPO treatment may also improve post-ischemic contractile recovery, acutely following I/R injury and sought to delineate the major cell-signaling cascades involved in improved outcome. Moreover, we investigated different doses and times of EPO administration relative to I/R injury to elucidate the most optimal protection scenario afforded by this cytokine. Since both cardiomyocytes and cardiac fibroblasts may contribute to postischemic ventricular remodeling, we extended our investigation to include an in vitro analysis of EPO-EPO-R signaling in these cells as a potential mediator of EPO's cardioprotection in vivo.
Our results indicate that a single dose of EPO can activate cell survival pathways in the rabbit heart in vivo and also positively affect post-I/R ventricular dysfunction. Moreover, EPO directly activates similar pathways in adult cardiac fibroblasts suggesting that these cells may mediate, at least in part, EPO's cardioprotective effects.
Experimental procedures Materials
Isoproterenol (ISO), Heparin, and PDGF were purchased from Sigma. Polyclonal antiphospho-STAT3, anti-phospho-STAT5, anti-STAT3 and anti-STAT5 used for immunoblotting of STAT3 and STAT 5 respectively were from Cell Signaling (Beverly, Massachusetts).
Polyclonal anti-phospho Jak1, anti-phospho Jak2, anti-Jak1, and anti-Jak2 are from Biosource International (Camarillo, California). Polyclonal anti-phosphorylated ERK, polyclonal antiphosphorylated Akt, and polyclonal anti-Akt from Cell Signaling Technology (Beverly, Massachusetts) and polyclonal anti-ERK2 from Santa Cruz Biotechnology were used for ERK and Akt activation assay. 
Induction of I/R
Animals used in this study were adult male New Zealand White rabbits (2.5-3.5 kg), and all procedures were performed in accordance with the regulations adopted by the National
Institutes of Health and approved by the Animal Care and Use Committee of Duke University.
Rabbits were sedated with a mixture of ketamine (30 mg/kg) and acepromazine (0.05 mg/kg), intubated and mechanically ventilated. Inhalation anesthesia (Isoflurane) was initially set at 3%
and subsequently reduced to 1.5% upon entry into the pleural space. A left thoracotomy and pericardiotomy was performed in all animals (n=35). After an intravenous heparin bolus (70 U/kg), the dominant marginal branch of the left circumflex coronary artery (LCx) was temporarily ligated with a pledgeted 5-0 prolene suture secured by a keeper. Regional ischemia was induced for 30 minutes followed by reperfusion. Animals were preoperatively randomized Parsa et al. Revised M3:14099 Page 6 to receive a single dose of EPO (1,000 U/kg or 5,000 U/kg; n=27) either 12 hours prior to ischemia, at the time of ischemia or at the time of reperfusion (Table 1) . Control animals (n=8) received normal saline (3 ml) at the time of ischemia. Rabbits were sacrificed on post-operative day 3 and their hearts harvested for area at risk and infarction quantification.
Assessment of LV Area at Risk
At the start of reperfusion, a marking stitch was left at the site of occlusion and on postoperative day 3, the animals were sacrificed and their hearts harvested. The area of the LV at risk for ischemic injury was stained as described using triphenyltetrazolium (TTC) staining, followed by counter-staining with pthalo-blue (22) . The heart was then dissected, cut into five or six 2-mm-thick transverse slices, fixed, and digitally photographed as described (22) . Total weights of area at risk were obtained and the area of necrosis were then blindly calculated and expressed as % of total LV weight (22) using Adobe Photoshop 6.0 (Adobe Systems Inc., San Jose, California).
Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End-Labeling (TUNEL)
A separate cohort of animals underwent TUNEL quantification. Rabbits were treated with EPO 1,000 U/kg (n=4) or normal saline (n=4) 12 hrs prior to LCx I/R and survived for 24
hr. Histologic heart samples were frozen in cryomolds and TUNEL labeling was performed on 5 magnification. Twenty-five random high-power fields in the peri-ischemic zone of each heart sample were chosen and blindly quantified.
In vivo hemodynamic measurements
Prior to intubation and thoracotomy each acute I/R animal underwent LV catheterization via left common carotid artery cutdown. LV pressure, LV end-diastolic pressure (EDP) and heart rate (HR) were measured by a 2. 
Cell Culture
Rabbit cardiac fibroblasts were prepared by the methods of Kim et al. (24) . Isolated cardiac fibroblats were maintained in DMEM (Invitrogen) supplemented with 1%
penicillin/streptomycin and 10% fetal bovine serum. For signaling assays, only early passage (<3) cells were used. The purity of these cultures was >95% cardiac fibroblasts as measured by vimentin expression and negative markers: desmin (myocytes), smooth muscle -actin (vascular smooth muscle cells), and von Willebrand Factor (endothelial cells) as previously described (24) .
Protein Immunoblotting
Western blotting was performed for ERK, Akt, Jak1, Jak2, Stat3, and Stat5 activation using specific anti-phosphorylated antibodies as described (7). Briefly, tissue samples were homogenized in lysis buffer, containing 50mM HEPES pH 7.5, 150mM NaCl, 1% Triton X-100, 1mM EDTA, 10% glycerol, 10mM sodium pyrophosphate, 2mM sodium orthovanadate, 10mM sodium fluoride, 1mM phenylmethylsulfonyl fluoride and 10µg/ml aprotinin, centrifuged at 18,000 g for 20 min at 4°C, and the resulting supernatants were collected. 20µg of proteins from tissues were subjected for standard SDS-PAGE immunoblotting. Cultured adult rabbit cardiac fibroblasts were serum starved in DMEM with 0.1% bovine serum albumin (BSA) for 72 hr.
Serum starved cells in 6 well plates were stimulated with EPO (4 or 10 unit/ml) for 5 min at 37°C.
After lysis, equivalent amounts of protein were applied for 4-20% SDS-PAGE gels.
Phosphorylated protein was then visualized by enzyme-linked chemiluminescence (ECL,
Amersham) and quantified by scanning laser densitometry and normalized to the levels of total protein also determined by protein immunoblotting (7, 24) .
DNA synthesis

DNA synthesis was determined as incorporation of [ 3 H]-thymidine into trichloroacetic
acid (TCA)-insoluble material as described (7, 24) .
Statistical Analysis
I/R hemodynamic data was analyzed using 2-way ANOVA (group vs. time) with repeated measures predetermined pair-wise comparisons with Bonferonni correction.
Densitometry, apoptotic nuclei, fibroblast proliferation, and area at risk data are presented as For all analyses, P<0.05 was considered significant.
RESULTS
Cardiac Function Following I/R and EPO Treatment
All acute I/R rabbits underwent thoracotomy followed by a baseline hemodynamic recording. Each animal was then subjected to 30 min of ischemia followed by 45 min of reperfusion during which serial in vivo LV pressure data recordings were taken at the designated time points. A single dose of EPO (1,000 U/kg or 5,000 U/kg) was given at respective stages of the study (pre-ischemia, concurrent with ischemia, or prior to reperfusion, Table 1 ). The data indicates that the dosing scenarios in group 2 (12 hrs of EPO pre-treatment) and group 5 (EPO at the time of ischemia) ( Table 1) Enhanced LV dP/dt max through the reperfusion period was also mirrored by significantly enhanced LV relaxation (dP/dt min )in these two groups as compared to control animals ( Figure 1c ).
Given improved global cardiac function, these 2 groups (Group 2; 12 hr EPO pretreatment and Group 5; EPO at the time of ischemia) exhibited improved maintenance of peak intracavitary LV pressure (group 2, P=0.02; group 5, P=0.048) as compared to group 1 animals ( Figure 1d ). Groups 3, 4, and 6 did not exhibit any significant improvement in cardiac contractility or relaxation and behaved similar to control (group 1) rabbits (Table 2) . Importantly, there was no significant difference in heart rate amongst groups (P=0.48, Table 2 ). These results indicate that pre-treatment with a lower dose of EPO is similar in maintaining beneficial cardiac function to a higher dose given at the time of ischemia. Thus, EPO appears to have acute physiological effects in I/R if given prior to, and at the time of ischemia.
Infarct Size Following I/R Injury and EPO Treatment
Previously, we have shown that pre-treatment with EPO (1000-5000 U/Kg) significantly reduced infarct size after LCx occlusion (7). In the current study, we assessed LV infarct size as a percentage of the ischemic area at risk in the 6 experimental groups that underwent I/R injury ( Figure 2 ). The most significant protection was noted in group 2 (10.9±2.1% vs.
32.4±2.6%, control) implying that pre-conditioning with EPO 12 hrs before I/R is the most advantageous scenario for myocardial salvage. This is consistent with the optimal global cardiac function seen with this group (Figure 1 ) and also with our previous data demonstrating EPO's preconditioning effect after myocardial infarction (MI) (7).
Effect of EPO on Myocardial Apoptosis Following I/R Injury
Using the in vivo I/R model in rabbits, we directly assessed whether EPO is preventing ischemic myocardium from undergoing apoptosis. This represents our mechanistic hypothesis based on our previous findings after MI (7) Figure 3 ) signifying fewer apoptotic positive cells in the EPO treated I/R rabbit hearts. These results coincide with lower apoptosis seen in fetal cardiomyocytes following oxidative stress and hypoxia (6,7) as well as lower LV apoptosis seen acutely (6 hrs) after permanent LCx occlusion (7).
In Vivo Signaling Following I/R and EPO Treatment
It is well documented that ischemia evokes activation of cardiac cell survival pathways, including Jak/STAT, that mediate the cardioprotection afforded by ischemic preconditioning (11, 25) . Our in vivo data indicates that 30 min of ischemia and 20 min of reperfusion in the adult rabbit heart activate the intracellular kinase Jak2 and its downstream targets STAT3 and STAT5
( Figure 4) . Thus, I/R itself triggers activation of pro-survival pathways in an attempt to guard the heart against further injury. Alternatively, exogenous EPO administered to healthy adult rabbits significantly activates Jak/STAT signaling in vivo detectable at the time of sacrifice 12 hr later ( Figure 4) . Results indicate that Jak2 is the principle triggering kinase for this pathway and subsequent cardioprotection (Fig 4c) since Jak1 was not activated by EPO (nor I/R) (data not shown). STAT3, in particular, is robustly stimulated by EPO (6.79±3.06 fold over basal levels, magnitudes in the adult rabbit heart (Fig 4d) .
These findings reiterate previously reported data that Jak2 and STAT3 are intimately involved in myocardial ischemia and the cardioprotection afforded by early ischemic preconditioning (26) . Moreover, our data indicates that these pathways are also stimulated by EPO and represent a potential mechanism for the in vivo pharmacologic cardioprotection following I/R injury (Figs. 1-3 In addition to Jak/STAT signaling, we have previously identified the ERK MAP kinase and PI3-K/Akt pathways as being important in EPO's actions on cardiac cells both in vitro and in vivo (7). In the current study, we have also shown that I/R acutely stimulates phosphorylation of ERK and Akt in the intact rabbit heart ( Figure 5 ). Similar to I/R, pharmacologic pretreatment with EPO for 12 hrs also significantly activates ERK and Akt in vivo in the rabbit heart by 7.94 ± 2.1 and 1.51 ± 0.19 fold increase over basal levels, respectively ( Fig. 5a and b) . Overall, we demonstrate that EPO's preconditioning effect on the heart involves known intracellular kinases that protect the heart against ischemic injury, and mimic pathways stimulated by I/R itself presumably as an endogenous means to protect the heart.
EPO Signaling in Adult Cardiac Fibroblasts
The physiologic and mechanistic effects of exogenous EPO in rabbit hearts detailed above as well as previously reported MI data does not clearly elucidate which cardiac cell type(s)
is/are responsible for cardioprotection and enhanced post-ischemia ventricular function. While the effect of EPO on myocytes (6) and myoblasts (7) has been studied, the effect of EPO on the cardiac fibroblast, which also is a key myocardial cell involved in ischemic responses and remodeling, is not known. Initially, we examined the expression of EPO-R in isolated adult rabbit cardiac fibroblasts. As shown in Figure 6 , EPO-R expression level in cardiac fibroblasts was actually much higher than levels found in ventricular myocytes.
To verify the potential role of EPO in cardiac fibroblasts, we examined the activation of cellular kinases associated with EPO signaling. We found that EPO-R stimulation in cardiac fibroblasts leads to activation of the Jak2-STAT3 pathway akin to what we found in the intact heart after EPO administration above. EPO induced tyrosine phosphorylation of Jak2 by 2.77±0.55 fold increase over basal (P<0.01) (Fig. 7a) , while Jak1 remained at basal levels (data not shown). EPO also induced tyrosine phosphorylation and activation of STAT3 by 1.30±0.16
fold increase over basal (P<0.05) (Fig. 7b) , while activation of STAT5 was not detected after EPO in cardiac fibroblasts (data not shown). Interestingly, STAT5 was activated in whole heart lysates from rabbits administered exogenous EPO and thus, STAT 5 may be activated in cardiomyocytes to participate in EPO's cardioprotective effects.
Since the ERK and Akt pathways appear to be involved in EPO's anti-apoptotic and/or cell proliferation effect in cardiomyoblasts (7), we studied ERK and Akt activation in cardiac fibroblasts. In ERK activation, EPO exhibited a dose effect with 4 U/ml resulting in 1.76±0.33
fold increase over basal levels (P<0.05) and activation was increased with 10 U/ml (2.33±0.48 fold increase over control, P<0.05) ( Fig. 7c and d) . Further, we found that ERK activation by EPO in cardiac fibroblasts can be inhibited by pertussis toxin (PTx) implicating a heterotrimeric G protein component in EPO-R signaling (Fig. 7) . This is actually similar to previous findings in CHO cells where EPO activation of ERK was G i -dependent (27) . EPO also induces phosphorylation of Akt by 1.88 ± 0.42 fold increase over basal (n = 4, p <0.05) (Fig. 7e) .
Interestingly, Akt activation by EPO in cardiac fibroblasts was not affected by PTx (Fig 7e) .
Jak-STAT activation by EPO in cardiac fibroblasts was also PTx-insensitive. This data suggests that at least two distinct signaling cascades are stimulated by EPO-R activation in cardiac fibroblasts. Finally, we examined whether ERK MAPK activation in cardiac fibroblasts may be involved in cell proliferation. However, unlike other cell lineages including cardiomyoblasts (7), cardiac fibroblasts did not undergo proliferation in response to EPO (data not shown).
DISCUSSION
To date, ischemic or pharmacologic preconditioning remains the most reproducible and effective mechanism responsible for the acquisition of ischemic tolerance and has important therapeutic implications. Our results indicate that EPO activates cell survival pathways akin to ischemic preconditioning, resulting in inhibition of myocardial apoptosis in vivo, which translates into increased viable myocardium (decreased infarct size) and enhanced post-ischemic global systolic and diastolic function independent of hematocrit augmentation.
These in vivo cardioprotective effects of EPO following I/R injury are consistent with previous data demonstrated for irreversible coronary occlusion (7) . Others have utilized in vitro model systems to test and validate EPO's protective role in the ischemic heart (28, 29) . In our current study, EPO administration 12 hrs before I/R or during LCx occlusion, significantly limits infarct size and improves global LV function acutely after I/R. At other doses employed in this study, EPO administered at the time of reperfusion does not alter acute cardiac function but maintained a protective effect in terms of infarct size and incidence of apoptosis.
Myocardial I/R clearly results in cardiomyocyte dysfunction and cell death. However, it is also a potent stimulator of cell signaling pathways implicated in cardioprotection and preconditioning of the ischemic heart. As little as four minutes of I/R can induce Jak1, Jak2, STAT1 and STAT3 activation in murine myocardium (26) . Similarly, 30 min of I/R upregulated Jak2 and STAT3 phosphorylation in isolated rat hearts (30) . In our in vivo adult rabbit I/R model the Jak/STAT pathway, specifically Jak2 and STAT3 appear to be the most robustly phosphorylated downstream target. The Jak-STAT pathway has recently been implicated in cardiac ischemic preconditioning thereby reducing ischemic damage (26) as well as preventing apoptosis in cultured myocytes (31) . In vivo analysis revealed that EPO treatment for 12 hrs resulted in activation of Jak/STAT, ERK MAPK, and Akt kinase pathways, all of which can increase cell survival and mitogenic signaling. Akt activation is particularly interesting since we have previously shown that the PI3-kinase/Akt pathway is responsible in fetal cardiomyocytes for EPO's anti-apoptotic effect during hypoxia (7) . Other laboratories corroborate the importance of Akt in protecting ischemic myocardium (12, 28, 29) .
Decreased apoptosis does not solely account for the improved global cardiac function since some EPO treatment groups (all groups where EPO was given at the time of reperfusion)
did not have exhibit enhanced cardiac function despite reduced apoptosis and smaller resultant infarcts. Potentially, this may be due to other documented effects of EPO such as an increase in intracellular Ca 2+ (32, 33) . Alternatively, functional benefits for these doses of EPO may not be manifested until later. Our results do suggest that EPO is not an inotropic agent since altering the time of delivery and the dose delivered resulted in different hemodynamic findings amongst groups albeit a higher dose of EPO (5000 U/kg) at the time of ischemia results in appreciable contractile augmentation. Differing effects on acute post-I/R ventricular function notwithstanding, all doses and treatments with EPO did limit infarct size following I/R injury, consistent with recently published data (7). As per our previous studies, the effects of EPO in the ischemic heart are independent of hematopoiesis as hematocrit following a single dose does not rise in rabbits until day 4 (7).
To expand on potential mediators, we studied EPO signaling in primary cultures of adult rabbit cardiac fibroblasts. Previously, we have shown that EPO, via the PI3K-Akt pathway, can mitigate fetal cardiomyoblast apoptosis secondary to oxidative stress and hypoxia (7). Since cardiac fibroblasts constitute the most numerous cell type in the heart (34), and actively participate in post-ischemic remodeling, the response of these cells to EPO probably represents an important myocardial process contributing to post-ischemic inflammatory pathobiology.
Furthermore, fibroblasts elaborate a rich source of cytokines, chemokines, and growth factors.
Interestingly, EPO-R was expressed in higher densities in cardiac fibroblasts than myocytes suggesting that cardiac modulate (at least partially) EPO's effects in vivo in the heart.
In recent studies performed to define EPO-mediated regulation of the ERK cascade, several different pathways have been identified that can ultimately lead to ERK activation including PI3K, which may use an atypical protein kinase C for EPO-induced ERK activation in CHO-K1 cells (27) . All ERK pathways appear to be initiated through effectors binding to (36) and Bcl-xL up-regulation via caspase activities (37) , which may contribute to cell survival pathways consistent with our in vivo results. It is also of interest that EPO-dependent ERK activation is not PTx-sensitive in hematopoietic cells (38) , which indicates that cardiac fibroblasts have distinct EPO-mediated signaling pathways, perhaps specifically for cardioprotection.
The fact that we see in vivo activation of STAT5 in whole heart extracts and only STAT3 activation in cardiac fibroblasts suggest that fibroblasts are not sole mediators of EPO's signaling effects in the heart and thus, EPO may have direct effects on myocytes even though EPO-R expression is relatively lower in these cells. Endothelial cells are yet another potential effector cell for EPO in the heart. However, our results with cardiac fibroblasts indicate that EPO administration robustly stimulates critical kinase cascades implicated in survival as well as remodeling and point towards cardiac fibroblasts as critical effectors for the cardioprotection afforded by EPO. Overall, the notion that EPO can trigger signaling cascades in myocardium that renders the heart resistant to I/R injury suggests novel applications of EPO for protecting the ischemic myocardium in the clinical arena. Therapeutic exploitation would be conceptually appealing but is hindered by the paucity of current knowledge regarding its mechanism. Future experiments can be designed to investigate in vivo cellular targets for EPO in the ischemic heart.
In summary, EPO can reduce infarct size, cardiomyocyte apoptosis, and mitigate ventricular dysfunction post-I/R injury. This study identifies potential signaling mechanisms whereby the heart adapts to stress in vivo and in cardiac fibroblasts in vitro. Thus, a window of therapeutic opportunity may exist where a single dose of EPO following an ischemic cardiac event (such as cardiac surgery or acute coronary syndromes) may offer acute protection as well as long-lasting benefit through preservation of viable myocardium during the I/R period.
Finally, the effect of EPO in the injured heart also strongly suggests the concept that EPO is a tissue-protective cytokine for other organs that express the EPO-R. activation over basal levels at 4U/ml and 10U/ml EPO and this ERK activation is inhibited by 100 ng/ml PTx. e) 10U/ml EPO also induced Akt phosphorylation at S473 and this was unaffected by 100 ng/ml PTx. fold increase over basal *
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